VRI to use Proteome Systems platform to develop diagnostics
Wednesday, 27 November, 2002
VRI BioMedical and Proteome Systems have signed a non-binding heads of agreement for a collaboration to develop some of VRI's diagnostic tests as point-of-care applications using Proteome Systems' proprietary diagnostic test platform.
"We have IP for a range of diagnostic tests which are ideal for point-of-care applications," explained VRI chief operating officer Dr Peter French.
He said the company had developed a number of lab-based diagnostic tests for a variety of medical conditions, including cancer.
"We have a couple of commercial partners interested in our diagnostic technology if we can supply it as a point-of-care diagnostic, and Proteome Systems has an appropriate rapid diagnostic platform," French said.
Leon Ivory, executive chairman of VRI, said that the agreement would accelerate commercialisation of VRI's diagnostic program and would generate significant commercial benefits to both companies.
French said that while details of the project were still confidential, co-development of the tests had already commenced. He said that a binding agreement would probably be in place in a few weeks.
Vanillin flavouring in vapes may disrupt embryo development
Vanillin — a common flavouring chemical in e-cigarettes — may disrupt the normal...
Heart valve tissues created from stem cells
The breakthrough should help advance our understanding into how human heart valves develop,...
Breast augmentation procedure uses 3D-printed scaffolds
3D-printed scaffold technology from medtech company BellaSeno has been used in a primary breast...
